Branded Generics Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	176 Pages	Coherent Market Insights	June, 2023	CMI18049273

Best Price Guarantee
Price	from $4,500
Length	176 Pages
Publisher	Coherent Market Insights
Published Date	June, 2023
SKU	CMI18049273

Branded Generics Market, By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Others) By Formulation (Oral, Parenteral, Topical and Others), By Indication (Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics and Anti-inflammatory, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Branded generic is a generic drug, which is manufactured by either original manufacturer after patent expiry of the brand, or is manufactured by a generic manufacturer. Branded generic has to go through abbreviated new drug application (ANDA) process before it can be marketed. Branded generic are cheaper than their branded counterparts but can be costlier than generic versions of the drug. Branded generic is defined as a product that is a novel dosage form of a branded off-patent medicine, and is manufactured by a different manufacturer than originator, or a molecule copy of an off-patent product with a trade name. Branded generics can also be different salts of an FDA-approved brand name drug.

It is easy to confuse branded generics with authorized generics, but they are not the same. Branded generics go through the same FDA approval process as other generics after branded drug patents expire. Authorized generics, however, are created by makers of branded drugs, under the same NDA (New Drug Approval) authorization as the original branded drug, and they may be sold before drug patents expire.

Market Dynamics

Rising ANDA approvals is a major factor which is supporting the market growth. According to an article published by Delhi Pharmaceutical Sciences & Research University on March 7 2023, a total of 742 Abbreviated New Drug Application (ANDA) approvals were granted during the calendar year 2022, registering a growth of 17% over last year. Additionally, 136 Tentative Approvals were also granted, again a similar growth over 2021 numbers (117) as seen for final ANDA approvals. Indian players contributed a large proportion of the incremental number of approvals this year with 88 more approvals than last year. Additionally, demand for generic medications is in surge owing to the affordable prices of branded generics.

Key features of the study:

This report provides an in-depth analysis of the global branded generics market and provides market size (US$ Million) and compound annual growth rate (CAGR) of 7.30% for the forecast period (2023–2030), considering 2022 as the base year.

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.

It profiles key players in the global branded generics market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies.

Key companies covered as a part of this study include Mylan N.V, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Aspen Pharmacare Holding Ltd., Abbott Laboratories, and Valeant Pharmaceuticals International, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.

Global branded generics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global branded generics market.

Detailed Segmentation:

Global Branded Generics Market, By Drug Class:

Alkylating Agents

Antimetabolites

Hormones

Anti-Hypertensive

Lipid Lowering Drugs

Anti-Depressants

Anti-Psychotics

Anti-Epileptics

Others

Global Branded Generics Market, By Formulation:

Oral

Parenteral

Topical

Others

Global Branded Generics Market, By Indication:

Oncology

Cardiovascular Diseases

Diabetes

Neurology

Gastrointestinal Diseases

Dermatology Diseases

Analgesics and Anti-inflammatory

Others

Global Branded Generics Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Drug Stores Global Branded generics Market, By Region:

North America

By Country:

U.S.

Canada

Latin America

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

Europe

By Country:

Germany

U.K.

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific

By Country

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East

By Country:

GCC

Israel

Rest of Middle East

Africa

By Country/Region:

South Africa

Central Africa

North Africa

Company Profiles

Mylan N.V*

Company Highlights

Products Portfolio

Key Highlights

Financial Performance

Strategies

Novartis AG

Teva Pharmaceutical Industries Ltd.

Pfizer Inc.

Sun Pharmaceutical Industries Ltd.

Aspen Pharmacare Holding Ltd.

Abbott Laboratories

Valeant Pharmaceuticals International, Inc

“*” marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Drug Class; Market Snapshot, By Formulation; Market Snapshot, By Indication; Market Snapshot, By Distribution Channel; Market Snapshot, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Recent Product Launches; Epidemiology; Merger, Acquisition, and Collaborations; Regulatory Scenario; Key Developments; PEST Analysis
4. Global Branded Generics Market– COVID-19 Impact Analysis: Economic Impact; COVID-19 Epidemiology; Impact on Supply and Demand
5. Global Branded Generics Market, By Drug Class, 2018 – 2030, (US$ Million): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018–2030; Segment Trends; Alkylating Agents; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Antimetabolites; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Hormones; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Anti-Hypertensive; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Lipid Lowering Drugs; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Anti-Depressants; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Anti-Psychotics; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Anti-Epileptics; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
6. Global Branded Generics Market, By Formulation, 2018 – 2030, (US$ Million): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018–2030; Segment Trends; Oral; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Parenteral; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Topical; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
7. Global Branded Generics Market, By Indication, 2018 – 2030, (US$ Million): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018–2030; Segment Trends; Oncology; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Cardiovascular Diseases; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Diabetes; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Neurology; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Gastrointestinal Diseases; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Dermatology Diseases; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Analgesics and Anti-inflammatory; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
8. Global Branded Generics Market, By Distribution Channel, 2018 – 2030, (US$ Million): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018–2030; Segment Trends; Hospital Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Retail Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Online Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Drug Stores; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
9. Global Branded Generics Market, By Region, 2018 – 2030, (US$ Million): Introduction; Market Share Analysis, By Region, 2023 and 2030 (%); Y-o-Y Growth Analysis, For Regions, 2018–2030; Regional Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 – 2030, (US$ Million); U.S.; Canada; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018– 2030, (US$ Million); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018– 2030, (US$ Million); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018– 2030, (US$ Million); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018– 2030, (US$ Million); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018– 2030, (US$ Million); North Africa; Central Africa; South Africa; 10. Competitive Landscape; Mylan N.V; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Novartis AG; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Teva Pharmaceutical Industries Ltd; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Pfizer Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Sun Pharmaceutical Industries Ltd.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Aspen Pharmacare Holding Ltd.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Abbott Laboratories; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Valeant Pharmaceuticals International, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; 11. Section; Research Methodology; About Us; *Browse 34 market data tables and 22 figures on “Global Branded Generics Market” - Global forecast to 2030